Market Research Report
Coccidioidomycosis - Pipeline Review, H1 2018
|Published by||Global Markets Direct||Product code||474980|
|Published||Content info||45 Pages
|Coccidioidomycosis - Pipeline Review, H1 2018|
|Published: February 20, 2018||Content info: 45 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Coccidioidomycosis - Pipeline Review, H1 2018, provides an overview of the Coccidioidomycosis (Infectious Disease) pipeline landscape.
Coccidioidomycosis, also called Valley fever, is an infection caused by the fungus Coccidioides. Symptoms include fever, cough, chest pain, chills, headache, fatigue and joint aches. Risk factors include weakened immune system, age, pregnancy, race and environmental exposure. Treatment includes antifungal medications.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Coccidioidomycosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Coccidioidomycosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Coccidioidomycosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Coccidioidomycosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Coccidioidomycosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.